<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Approximately 10% of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> demonstrate microsatellite instability (MSI) </plain></SENT>
<SENT sid="1" pm="."><plain>Distinct from the majority of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> with <z:mp ids='MP_0008866'>chromosomal instability</z:mp> (CIN) which harbour allelic imbalance from chromosomal <z:mp ids='MP_0004025'>polyploidy</z:mp> and <z:mp ids='MP_0004024'>aneuploidy</z:mp>, MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> retain intact chromosomal numbers but contain microsatellite repeats due to deficiency in mismatch repair which are thought to contribute to the early steps of <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">tumourigenesis</z:e> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>While emerging clinical data has highlighted improved prognosis of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with MSI in early <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and potentially circumventing the need for adjuvant chemotherapy, the implications of MSI deficiency in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) remain uncertain </plain></SENT>
<SENT sid="3" pm="."><plain>In order to assess the significance of MSI in mCRC, a broad literature review was carried out through online PubMed search on published articles encompassing pathological and clinical papers </plain></SENT>
<SENT sid="4" pm="."><plain>This included pathological studies identifying the correlation with MSI status between primary sites and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, and chemotherapeutic studies assessing the impact of fluoropyrimidine-, irinotecan- and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based regimens on mCRC with MSI </plain></SENT>
</text></document>